Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35174853)

  • 1. K-Ras and p53 mouse model with molecular characteristics of human rhabdomyosarcoma and translational applications.
    Nakahata K; Simons BW; Pozzo E; Shuck R; Kurenbekova L; Prudowsky Z; Dholakia K; Coarfa C; Patel TD; Donehower LA; Yustein JT
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35174853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
    Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
    Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
    Yu L; Wang J
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of a muscle ankyrin-repeat protein, Arpp, in paraffin-embedded tumors: evaluation of Arpp as a tumor marker for rhabdomyosarcoma.
    Ishiguro N; Motoi T; Osaki M; Araki N; Minamizaki T; Moriyama M; Ito H; Yoshida H
    Hum Pathol; 2005 Jun; 36(6):620-5. PubMed ID: 16021567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS).
    Tsintari V; Walter B; Fend F; Overkamp M; Rothermundt C; Lopez CD; Schittenhelm MM; Kampa-Schittenhelm KM
    BMC Cancer; 2022 Jul; 22(1):725. PubMed ID: 35780096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing undifferentiated embryonal sarcoma of the liver from biliary tract rhabdomyosarcoma: a Children's Oncology Group study.
    Nicol K; Savell V; Moore J; Teot L; Spunt SL; Qualman S;
    Pediatr Dev Pathol; 2007; 10(2):89-97. PubMed ID: 17378682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.
    Tuohy JL; Byer BJ; Royer S; Keller C; Nagai-Singer MA; Regan DP; Seguin B
    Vet Pathol; 2021 May; 58(3):516-526. PubMed ID: 33691532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
    McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
    Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
    Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
    Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
    Folpe AL; McKenney JK; Bridge JA; Weiss SW
    Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
    Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
    Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma.
    Hosoyama T; Aslam MI; Abraham J; Prajapati SI; Nishijo K; Michalek JE; Zarzabal LA; Nelon LD; Guttridge DC; Rubin BP; Keller C
    Clin Cancer Res; 2011 May; 17(9):2757-66. PubMed ID: 21536546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
    Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
    Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing K-RasG12V and deficient in p53.
    Saito H; Suzuki N
    Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.
    Blum JM; Añó L; Li Z; Van Mater D; Bennett BD; Sachdeva M; Lagutina I; Zhang M; Mito JK; Dodd LG; Cardona DM; Dodd RD; Williams N; Ma Y; Lepper C; Linardic CM; Mukherjee S; Grosveld GC; Fan CM; Kirsch DG
    Cell Rep; 2013 Nov; 5(4):933-40. PubMed ID: 24239359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
    Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
    Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental induction of rhabdomyosarcoma in mice with fractionated doses of beta-irradiation.
    Gupta A; Andrews KL; McDaniel KM; Nagle RB; Bowden GT
    J Cancer Res Clin Oncol; 1999; 125(5):257-67. PubMed ID: 10359130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. You can win by losing: p53 mutations in rhabdomyosarcomas.
    Post SM; Lozano G
    J Pathol; 2010 Oct; 222(2):124-8. PubMed ID: 20821751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior.
    Staibano S; Franco R; Tranfa F; Mezza E; Lo Muzio L; Strianese D; Errico ME; Bufo P; Ferrara G; Somma P; Mansueto G; Greco I; Fiorillo A; Bonavolontà G; De Rosa G
    Anticancer Res; 2004; 24(1):249-57. PubMed ID: 15015604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.